Lung cancer is now the number one cause of cancer death for both men and women. An age-adjusted analysis over the past 25 years shows that in women speci®cally, lung cancer incidence is on the rise. It is estimated that 10 ± 20 genetic events including the alteration of oncogenes and tumor suppressor genes will have occurred by the time a lung tumor becomes clinically evident. In an eort to identify regions containing novel cancer genes, chromosome 18p11, a band not previously implicated in disease, was examined for loss of heterozygosity (LOH). In this study, 50 matched normal and NSCLC tumor samples were examined using six 18p11 and one 18q12.3 PCR-based polymorphic markers. In addition, LOH was examined in 29 glioblastoma pairs and 14 paired breast carcinomas. This analysis has revealed potentially two regions of LOH in 18p11 in up to 38% of the tumor samples examined. The regions of LOH identi®ed included a 2 cm area between markers D18S59 and D18S476, and a more proximal, 25 cm region of intermediate frequency between D18S452 and D18S453. These results provide evidence for the presence of one or more potential tumor suppressor genes on the short arm of chromosome 18 which may be involved in NSCLC, brain tumors and possibly breast carcinomas as well.
Introduction
An estimated 178 000 new lung cancer cases are expected in the United States in 1997 with 80% of these histologically designated as Non-small cell lung carcinomas (NSCLC). In the same year, more than 160 400 individuals are expected to die of lung cancer, making this disease the number one cause of cancer death for both men and women (Parker et al., 1997) . The 86% mortality rate for NSCLC has remained fairly constant since 1980 despite advances in cytotoxic drug development, radiotherapy and patient management. This may be due, in part, to the lack of information about genetic loci involved in its pathogenesis. Current theories suggest that as many as 10 ± 20 events including alterations of oncogenes and tumor suppressor genes will have occurred by the time lung cancer is clinically evident (Minna et al., 1991) . Tumor suppressor genes involved in NSCLC have been located on chromosome bands 3p, , 5q (Fong et al., 1995a) , 9p Center et al., 1993), 11p (Tran and Bepler and Garcia-Blanco, 1994) , 11q (Rasio et al., 1995) , and 17p and 17q (Fong et al., 1995b) .
Molecular evidence supporting a role for genes on chromosomal arm 18p in NSCLC is scarce. Several cytogenetic analyses on primary NSCLC tumor samples have revealed that chromosome 18 is one of several chromosomes preferentially lost as a result of tumorigenesis (Testa et al., 1992 (Testa et al., , 1994 . Chromosome 18 was lost in approximately 35% of the 63 primary tumor samples analysed cytogenetically. Other signi®cant losses were measured for chromosomes 9, 13, 21, and 22 (Testa et al., 1994) . Another study of pleural eusions containing metastatic or invasive NSCLC tumor cells detected chromosome 18 loss at a frequency of 45% in all histological subtypes of lung cancer. In addition, chromosome 18 structural rearrangements have been found to be rare events, suggesting that loss of a gene(s) on this chromosome is an important mutational event in the tumorigenic process (Merlens et al., 1997) . Previous loss of heterozygosity studies on NSCLC have identi®ed allelic deletions on chromosome 18q (Shiseki et al., 1996; Nagatake et al., 1996a,b) but not on chromosome 18p, although often only one 18p marker has been analysed. However, in one analysis of 29 in®ltrating ductal carcinomas of the breast, LOH on band 18p was measured at 62% (with 14.5% being con®ned to the distal region of 18p), indicating a putative tumor suppressor gene may reside in this region of the chromosome (Huang et al., 1995) .
To further investigate the presence of potential novel tumor-related genes in chromosomal band 18p11, we examined 50 matched normal and NSCLC tumor samples as well as 29 glioblastoma pairs and 14 paired breast carcinoma samples for loss of heterozygosity (LOH) using six 18p11 and one 18q12.3 PCR-based polymorphic markers. This study revealed two potential regions of LOH on chromsomal band 18p11 in these various tumor types.
Results

Loss of heterozygosity on chromosome 18p11 in NSCLC
Matched pairs of normal/tumor DNA from 50 NSCLCs, 29 astrocytomas and 14 breast carcinomas were assessed for allelic deletions at six polymorphic marker loci spanning chromosome band 18p11 and one marker in 18q12.3. Our set of NSCLC tumors included 18 squamous cell, 23 adenocarcinoma, two large cell and seven undi subtypes. The overall frequency for LOH on 18p11 in NSCLC was 38% (19/50). As whole sample DNA extracts were used for these analyses, normal in®ltrating cells would be expected to potentially mask a percentage of tumor cells exhibiting LOH. Most likely therefore our reported frequencies are under estimates.
Frequencies for individual marker loci in all NSCLCs ranged from 11 ± 32% with peaks at D18S476 (32%) in 18p11.3 and D18S452 (21%) in 18p11.2 ( Figure 1 ). As the LOH frequency dropped between these two markers (10% at D18S52) this suggests the presence of two potential tumor suppressor genes on chromosome 18p. In our set of tumors, LOH appeared more frequently in adenocarcinomas [48% (11/23)] than in squamous cell carcinomas [28% (5/18)] although the number of individual tumor subtypes analysed is small. Isolation of the tumor suppressor genes corresponding to these deleted regions will determine whether a real subtype speci®city exists for these LOH regions. One tumor, 2503T, exhibited microsatellite instability at all markers examined in 18p11 (data not shown) and was not included in the remaining data analysis.
Examples of allelic patterns for critical NSCLC samples are shown in Figure 2 with the corresponding densitometrically determined reductions in allelic ratios. In 7/19 (32%) tumors, allelic deletion was restricted to the most distal regions of 18p as indicated by maintenance of heterozygosity at markers distal to or at D18S453 in 18p11.2. These results are not evidence however of the absence of LOH in 18q, as only the 18q12.3 marker D18S57 was analysed in this study. Several other reports looking at NSCLC and breast carcinomas have shown that LOH can be present on both the long and short arms of a chromosome either independently or concommittantly (Huang et al., 1995; Hampton et al., 1994) . Our data indicate that only 11% (2/19) of NSCLC tumors are suggestive of whole chromosome 18 loss based on the markers analysed.
Two potential regions of LOH in chromosome 18p11
This analysis raises the possibility that two regions of LOH exist in NSCLCs and brain tumors. Figure 3 schematically depicts the regions of allelic deletion for the 19 NSCLC tumors in which LOH was measured in 18p11. Region 1 (the telomeric region) is de®ned by markers D18S59 and D18S476, an area encompassing 2 cm. Speci®c examples of Region 1 LOH are shown in adenocarcinomas 1N/T and 1910B/C, squamous cell carcinoma 71/70 and undierentiated NSCLCs 142/141 and 28N/T. The second region, of intermediate LOH frequency, is located proximal to D18S452 and distal to D18S453, a region involving 25 cm of sequence. LOH encompassing both Regions 1 and 2 was detected in 68% (13/19) of tumors whereas 26% (5/19) showed LOH only in the most distal region. Only one NSCLC tumor (5%) underwent allelic deletion of the second LOH region alone. Of the 13 tumors with LOH involving both Regions 1 and 2, the deletion event was continuous in 31% (4/ 13) and discontinuous in the remaining 69% (9/13) suggesting independent genetic events were responsible for two thirds of the multiple allelic deletions found in 18p. The prevalence for deletion of both regions in NSCLC tumors may indicate that alteration of both tumor suppressor genes is necessary for tumor formation. It might also be that alteration of the gene in Region 1 preceeds and/or potentially aects the alteration of sequences positioned in Region 2. Given the proximity of these two regions however, it may also be envisioned that genetic alteration in one region aects the stability of nearby sequences via secondary structures generated during mitotic recombination.
Loss of heterozygosity on 18p11 in gliomas and breast carcinomas
To determine if the chromosome 18 LOH regions were speci®c to NSCLCs or represented alterations aecting sequences which might be important in other adult neoplasms, we analysed 29 normal/tumor paired gliomas and 14 normal/tumor paired breast carcinomas. Glioma specimens were categorized according to the WHO grading system (Kleihues et al., 1993) . In gliomas, the overall frequency of LOH was 31%(9/29). LOH in Region 1 alone, Region 2 alone, and both regions together occurred at approximately the same frequency (33%, 22% and 44% respectively). LOH did not appear to exhibit grade-speci®city as allelic deletions were detected in 1/2 As, 3/8 AAs and 5/19 GBMs.
Of the 14 invasive ductal breast carcinomas analysed, LOH was identi®ed in 21% (3/14). No breast tumors showed LOH encompassing both Regions 1 and 2 or involving Region 2 alone. The smallest region of overlap for Region 1 (for tumors 1, 7, and 8) was distal to D18S481 in 18p11.3. In addition to allelic deletion, 14% of these breast tumors displayed microsatellite instability (MI) for multiple chromosome 18p loci. A literature search revealed only one previous analysis which reported a MI frequency of 4% for this chromosome in breast tumors (Huang et al., 1995) . No examples of MI were found in the gliomas studied, consistent with other published frequencies (1 ± 8%) (Zhu et al., 1996) . Only 1/50 (2%) (tumor 2503) of the NSCLC tumors Figure 2 Examples of tumors critical in de®ning the minimal regions of LOH on chromosome band 18p11 in Non-small cell lung carcinomas, gliomas and breast carcinomas. Autoradiographs represent normal (N) and matched tumor (T) DNA samples from patients whose case numbers are shown to the left. Chromosome 18 locus names appear at the top, ordered from most telomeric (D18S59) to most proximal (D18S453). Densitometrically calculated allelic reductions (D) in the intensity of alleles between tumor and normal DNA samples is shown below each autoradiograph. A value greater than 0.5 was indicative of LOH; .04-.05 indicated allelic imbalance; 50.4 was evidence of maintenance of heterozygosity showed MI and this aected all loci analysed. Reported MI frequencies for NSCLC have been quite variable, ranging from 6.5 ± 34% for primary tumors (Fong et al., 1995b; Adachi et al., 1995; Shridhar et al., 1994) and up to 55% in metastases (Adachi et al., 1995) , depending on the markers analysed. None of these previous analyses on NSCLCs and brain tumors utilized markers from chromosome 18p.
Discussion
The results of this study provide evidence for the presence of one or more tumor suppressor genes on the short arm of chromosome 18p which may be involved in NSCLC, brain tumors and possibly breast carcinomas as well. The analysis also serves to de®ne the location of these putative tumor suppressor genes to a 2 cm distal region between D18S59 and D18S476 Figure 3 Schematic representation of the regions of allelic deletion measured in nineteen Non-small cell lung carcinomas (NSCLC), separated by subtype. The 18p loci analysed are shown telomeric (left) to centromeric (right) along the top. Tumor cases are identi®ed by the numbers shown to the left. Shaded areas indicate the two distinct regions of LOH de®ned in this analysis. Closed circles, loss of heterozygosity; Striped circles, allelic imbalance; Open circles, maintenance of heterozygosity; Dotted circles, not informative; ND, not done in 18p11.3 and a 25 cm region between D18S452 and D18S453 in 18p11.2. This is the ®rst description of loss of heterozygosity aecting the short arm of chromosome 18p in either NSCLCs or primary brain tumors. One previous study on in®ltrating ductal carcinoma of the breast, showed an overall frequency of 62% LOH for chromosome 18 with allelic deletion con®ned to distal 18p in 14.5% of the cases (Huang et al., 1995) although only a few markers in distal 18p were utilized. No apparent association between chromosome 18 LOH and tumor status, tumor size, lymph node involvement or metastases was detected.
Tumors with LOH maintained heterozygosity for at least one marker on chromosome 18 in 16/19 (84%) of NSCLC tumors and in 7/9 (78%) of brain tumors. Such retention indicates that loss of the whole chromosome 18 is a rare event in NSCLC. Intrachromosomal deletion has also been reported as the majority of LOH events on chromosome 11 in lung and breast cancer (Winqvist et al., 1995; Shridhar et al., 1994) . This is in contrast to the mutational events leading to LOH on chromosome 3 in NSCLC (Rabbitts et al., 1990) and chromosome 10 in malignant meningiomas (Rempel et al., 1993) where whole chromosome loss rather than regional deletion appears to be the underlying mechanism of choice.
By analysing a series of six markers in 18p11, two potential regions of LOH were discovered. Region 1 (the telomeric region) is de®ned by markers D18S59 and D18S476, an area representing 2 cm. Region 2 is proximal to D18S452 and distal to D18S453 in chromosome band 18p11.2, was of intermediate frequency, and encompassed 25 cm of sequence. In NSCLCs, two-thirds as many tumors displayed LOH Figure 4 Schematic representation of the regions of allelic deletion discovered in nine astrocytomas and three breast carcinomas. The 18p loci analysed are as in Figure 3 . Tumor cases are identi®ed by the numbers shown to the left. Shaded areas indicate distinct regions of LOH. Circles are as described in Figure 3 . MI, microsatellite instability; ND, not done; A, Astrocytoma; AA, Anaplastic Astrocytoma; GBM, Glioblastoma multiforme in both Regions 1 and 2 (68%) as for Region 1 alone (26%) whereas only 5% (1/29) underwent allelic deletion of the second LOH region alone (Table 1) . Of the 13 tumors with LOH involving both Regions 1 and 2, the frequency of separate or continuous LOH in Regions 1 and 2 was dierent for dierent subtypes of lung tumors. For adenocarcinomas, 70% (6/9) were indicative of continuous loss while 30% (3/9) showed two independent regions of LOH. In contrast, only 25% (1/4) of tumors with a squamous histology had continuous allelic deletion whereas 75% (3/4) exhibited two separate LOH regions. It will be necessary to examine this particular characteristic in an expanded group of tumors but it may re¯ect a dierence in timing for the mutation of loci or a dierence in the mutational mechanisms aecting chromosome 18p in the cellular precursors to these speci®c lung tumor subtypes. The prevalence for deletion of both regions in NSCLC tumors may also indicate that alteration of both tumor suppressor genes is necessary for tumor formation. Since in 18/19 NSCLCs LOH never occurs in Region 2 without concomitant LOH in Region 1, one might propose that alteration of a gene in Region 1 preceeds and/or potentially aects the alteration of sequences positioned in Region 2 in NSCLCs.
In brain tumors, the overall LOH frequency was 31% (9/29). LOH encompassing both Regions 1 and 2 was twice as frequent (44%) as for Region 1 alone (22%), much the same as for NSCLC. However, 3/9 brain tumors (33%) had measurable LOH in Region 2 only, an uncommon event in NSCLCs and breast tumors. Additionally, continuous LOH of both regions was much more frequent (75%) than separate LOH events (25%) in brain tumors whereas these fractions were 31% and 69% in NSCLCs. And ®nally, LOH in Region 1 (3/14) alone was found only in breast carcinomas although the number of tumors analysed here was small. The tumor-and subtype-speci®c regional LOH dierences between gliomas, breast carcinomas and NSCLCs suggests these two putative tumor suppressor genes might play roles of varying importance in the tumorigenic process in dierent tissues. These dierences may also re¯ect mutational mechanisms speci®c to the individual tumor types, be suggestive of a preferential order of alteration for genes, or result from variating environmental exposures for the representative organ tissues.
The possibility of multiple LOH regions on 18p for both lung and brain tumors presents a scenario where LOH at these dierent loci could potentially occur on the same chromosome 18 concurrently or on separate chromosomal homologs. In breast carcinomas, some individual tumors have been found which exhibit chromosome 11p and 11q LOH at varying frequencies indicating that tumors can in fact be heterogeneous for these events and suggesting that multiple genetic events aecting the same chromosome can act independently of one another, contributing to the stepwise development of the fully malignant phenotype (Winqvist et al., 1995) . It would be of interest to analyse NSCLC tumors with distinct regions of LOH with regard to their inherited chromosome 18 haplotypes, to determine if the individual LOH regions are in fact independent events occurring on the same or separate chromosomes 18.
The biological importance of these putative loci and their clinical relevance in the pathogenesis of adult neoplasms is at present unclear. Their signi®cance will most appropriately be addressed once the corresponding tumor suppressor genes from these two distinct regions are isolated and analysed for functionality and mutational status. The narrow 2 cm LOH area reported for the most distal Region 1 should add focus to the search for such genes and help to decipher the mechanisms responsible for aecting chromosomal band 18p in tumors of the lung, brain and breast.
Materials and methods
Patient materials
Primary Non-small cell lung carcinoma and patientmatched normal lung tissue samples were obtained from 50 unselected patients upon surgical resection at the UCSD Medical Center as well as through the Cooperative Human Tissue Network Western Division at Case Western Reserve University. All samples, after surgical removal, were immediately snap-frozen in liquid nitrogen and stored at 7808C until further use. Each fresh lung tumor and accompanying normal tissue was histopathologically characterized at the time of surgery with informed consent and the corresponding pathology reports have been obtained.
Glioma specimens were divided immediately upon surgical removal. Partial tumor specimens were ®xed in 10% buered formalin and embedded in paran for pathological diagnosis. The remaining tumor tissue was immediately snapfrozen in liquid nitrogen and later processed for DNA as previously reported. Blood specimens were collected at the time of surgery and stored at 48C. Peripheral blood lymphocyte DNA was isolated within 3 days using a DNA extraction kit according to manufacturer's instructions (Stratagene). Institutional IRB-approved informed consent was obtained from all patients or the patient's guardian. Pathology reports were reviewed and specimens selected at random on the basis of availability of both normal and tumor DNA.
Primary breast cancer tissue along with matching peripheral blood lymphocytes were obtained with informed consent for tissue banking from patients receiving care at Duke University Medical Center. All tumors were characterized as in®ltrating ductal carcinomas by pathological examination. Samples were stored frozen until DNA extraction.
PCR analysis
DNA from each normal/tumor pair was subjected to PCR analysis using six chromosome 18p markers including D18S59, D18S476, D81S481, D18S52, D18S452, D18S453, and one 18q12.3 marker D18S57. The likely order of these markers and estimated interval distances are based on both GeÂ neÂ thon and CEPH linkage data (Rojas et al., 1995; Buetow et al, 1994; Gyapay et al., 1994) . Detailed ampli®cation information for all polymorphic markers used in this study were obtained from the Genome DataBase (Johns Hopkins University Medical School, Baltimore, MD, USA). Conditions for denaturation, annealing, and extension for each primer pair were essentially as reported except that 0.3 ± 1 unit of Perfect Match (Stratagene) was added to each reaction to optimize the equal ampli®cation of alleles. Primer end-labeling, ampli®cation reactions, and resolution of PCR products by denaturing electrophoresis were carried out as previously described (Besnard-GueÂ rin et al., 1996) .
LOH analysis
LOH for tumor DNA samples was assessed ®rst by visual inspection followed by densitometric con®rmation as described previously (Hampton et al., 1994) . When discordant results were obtained between visual and densitometric interpretations, PCR analyses were repeated with multiple exposures and a consensus result reported. Several chromosome 18p markers consistently resulted in unequally ampli®able alleles in the normal samples. Using a densitometer, the relative ratio of normal and tumor alleles was ®rst normalized and then compared. When the allelic ratio in the tumor DNA was reduced by more than 50% (D0.5) from that found in the normal DNA, this sample was denoted as having LOH at that locus. Allelic ratios reduced by between 40 ± 50% (D0.4 ± D0.5) were scored as allelic imbalances and interpreted as LOH with residual allele signals from contaminating normal tissue. Tumors with ratios less than 40% (5D0.4) were assigned as maintaining heterozygosity. By choosing a stringent allelic loss ratio (0.5, as compared to 0.3 in most other analyses) for determination of LOH, false negative LOH resulting from allele overlap with polymerase slippage bands should be minimized.
